col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: Publishing House OKI
  original article Journal Date Title Authors All Authors
1 [GO] Antibiotics and Chemotherapy 2021―Oct―21 Seaweed-Derived Sulfated Polysaccharides as Potential Agents for Prevention and Treatment of Influenza and COVID-19 N. N. Besednova, T. N. Zvyagintseva, B. G. Andriukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovsky, et al. (+2)
2 [GO] Antibiotics and Chemotherapy 2021―Oct―21 Problem of Drug Interactions in the Treatment of Patients with COVID-19 and Comorbid Conditions R. M. Aramisova, Z. A. Kambachokova, Z. A. Akhkubekova, L. L. Logvina, M. M. Sarbasheva, S. M. Chudopal, et al. (+4)
3 [GO] Antibiotics and Chemotherapy 2021―Oct―21 COVID-19 Therapy: the Role of Antirheumatic Drugs M. A. Litvinova, N. V. Muravyeva, B. S. Belov
4 [GO] Antibiotics and Chemotherapy 2021―Oct―21 Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters S. V. Chepur, A. V. Smirnova, A. N. Kirienko, I. A. Myasnikova, B. A. Kanevsky, P. V. Sorokin
5 [GO] Antibiotics and Chemotherapy 2021―Aug―30 Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 in vitro study V. S. Smirnov, I. A. Leneva, T. A. Kudryavtseva, E. B. Fayzuloev, V. A. Zaplutanov, S. V. Petlenko, et al. (+3)
6 [GO] Antibiotics and Chemotherapy 2021―Aug―30 Local antiviral activity of the drug «Thymogen®», nasal dosed spray, against SARS-CoV-2 coronavirus in vitro I. A. Leneva, V. S. Smirnov, T. A. Kudryavtseva, E. B. Fayzuloev, A. V. Gracheva, N. P. Kartashova, et al. (+2)
7 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2021―Aug―13 COVID-19: economic aspects of influenza vaccine prevention E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich
8 [GO] Antibiotics and Chemotherapy 2021―Jun―25 Possibilities of Hyperinflammation Correction in COVID-19 I. S. Simutis, G. A. Boyarinov, M. Yu. Yuriev, D. S. Petrovsky, A. L. Kovalenko, S. A. Parfenov
9 [GO] Antibiotics and Chemotherapy 2021―Jun―25 Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach K. A. Zykov, E. A. Sinitsyn, A. V. Rvacheva, A. O. Bogatyreva, A. A. Zykova, T. V. Shapovalenko
10 [GO] Antibiotics and Chemotherapy 2021―Jun―25 Polyphenols Sourced from Terrestrial and Marine Plants as Coronavirus Reproduction Inhibitors N. N. Besednova, B. G. Andryukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovskiy, L. N. Fedyanina, et al. (+3)
11 [GO] Pharmacokinetics and Pharmacodynamics 2021―Jun―23 Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues O. A. Limanova, O. A. Gromova, L. E. Fedotova
12 [GO] Antibiotics and Chemotherapy 2021―May―07 The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19 А. U. Sabitov, Р. V. Sorokin, S. U. Dashutina
13 [GO] Antibiotics and Chemotherapy 2021―May―07 The Prospects of Succinates’ Use under Hypoxic Conditions in COVID-19 Yu. Р. Orlov, V. V. Afanasyev, I. A. Khilenko
14 [GO] Antibiotics and Chemotherapy 2021―May―07 Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population А. I. Zagrebneva, Е. А. Baryakh, Е. I. Zhelnova, N. G. Poteshkina, I. Р. Beloglazova, Z. Yu. Mutovina, et al. (+8)
15 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2021―Mar―12 Socioeconomic and global burden of COVID-19 A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov
16 [GO] Antibiotics and Chemotherapy 2021―Feb―15 Cytokine Storm in the Novel Coronavirus Infection and Methods of its Correction A. V. Ershov, V. D. Surova, V. T. Dolgikh, T. I. Dolgikh
17 [GO] Antibiotics and Chemotherapy 2021―Feb―15 Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection K. V. Kasyanenko, O. V. Maltsev, K. V. Kozlov, I. I. Lapikov, N. I. Lvov, V. S. Sukachev, et al. (+3)
18 [GO] Antibiotics and Chemotherapy 2020―Nov―23 Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19 A. U. Sabitov, V. V. Belousov, A. S. Edin, E. V. Oleinichenko, E. P. Gladunova, E. P. Tikhonova, et al. (+3)
19 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19 V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
20 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of angiotensin II receptor blockers in patients with COVID-19 A. V. Matveev, V. A. Otdelenov, D. A. Sychev
21 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibilities for the use of tofacitinib in patients with COVID-19 A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
22 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev
23 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibilities for the use of anakinra in COVID-19 V. A. Otdelenov, A. V. Matveev, D. A. Sychev
24 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Rationality of routine clinical use of olokizumab in COVID-19 V. M. Tsvetov, A. V. Matveev, D. A. Sychev
25 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of colchicine in patients with COVID-19 Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev
26 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of umifenovir in patients with COVID-19 Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, et al. (+6)
27 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of vitamin D3 in patients with COVID-19 I. N. Sychev, A. V. Matveev, D. A. Sychev
28 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of dipyridamole in patients with COVID-19 I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
29 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Dexamethasone use in patients with COVID-19 V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
30 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of remdesivir in patients with COVID-19 V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
31 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of favipiravir in patients with COVID-19 A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
32 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Use of unlicensed drugs and off-label drug use: focus on COVID-19 S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko
33 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge A. V. Krykov, V. A. Otdelenov, D. A. Sychev
34 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis V. M. Tsvetov, I. N. Sychev, D. A. Sychev
35 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
36 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm» V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev
37 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Rationale for use mefloquine for COVID-19 treatment V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
38 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention K. B. Mirzaev, D. A. Sychev
39 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev
40 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Is it possible to use riamilovir to prevent infection and treat COVID-19? V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
41 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19? Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
42 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Could canakinumab be used for COVID-19? V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
43 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev
44 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel V. A. Otdelenov, A. V. Krykov, D. A. Sychev
45 [GO] Antibiotics and Chemotherapy 2020―Jun―08 Antiviral Activity of Kagocel® in vitro Against Virus SARS-CoV-2 S. Ya. Loginova, V. N. Shchukina, S. V. Savenko, S. V. Borisevich
46 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―May―30 Socio-economic burden of COVID-19 in the Russian Federation A. S. Kolbin, D. Yu. Belousov, Yu. M. Gomon, Yu. E. Balykina, I. G. Ivanov
47 [GO] Antibiotics and Chemotherapy 2020―May―25 Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome S. Ya. Loginova, V. N. Shchukina, S. V. Borisevich, R. A. Hamitov, V. A. Maksimov


[de][en]

Last change 2021―Sep―04 16:13:39 UTC

© Daten-Quadrat 2021       Done in 0.008 sec